Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2197-2208

  Woo, Ha Na ^a   Chung, Hye Kyung ^b   Ju, Eun Jin ^a   Jung, Joohee ^a,c   Kang, Hye Won ^d   Lee, Sa Won ^d   Seo, Min Hyo ^d   Lee, Jin Seong ^e   Lee, Jung Shin ^a,b   Park, Heon Joo ^f   Song, Si Yeol ^a   Jeong, Seong Yun ^a   Choi, Eun Kyung ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Duksung Women's University   (South Korea)

^d Samyang Corporation   (South Korea)

^e Research Institute of Radiology   (South Korea)

^f Inha University School of Medicine   (South Korea)

Author keywords

Anticancer; Polymeric nanoparticle; Radiotherapy; Sirolimus

Indexed keywords

NANOPARTICLE; POLYMER; RAPAMYCIN; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; METHOXY POLY(ETHYLENE GLYCOL) POLY(LACTIDE); METHOXY POLY(ETHYLENE GLYCOL)-POLY(LACTIDE); POLYESTER; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG TOLERABILITY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; LIGHT SCATTERING; LUNG ADENOCARCINOMA; MALE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG SCREENING; FEMALE; INJECTION; NANOMEDICINE; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; ULTRASTRUCTURE;

MAMMALIA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; POLYMERS; RADIATION-SENSITIZING AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866756419     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29480     Document Type: Article

References (35)

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-171.
3. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
4. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets. 2010;10(5): 484-495.
5. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005;65(16):7052-7058.
6. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg. 2009;6(2): 47-55.
7. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation. 2001;72(7):1181-1193.
8. Hoy SM, McKeage K. Temsirolimus: in relapsed and/or refractory mantle cell lymphoma. Drugs. 2010;70(14):1819-1829.
9. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004; 100(4):657-666.
10. Wang Y. Everolimus in renal cell carcinoma. Drugs Today (Barc). 2010;46(8):557-566.
11. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005;23(23):5386-5403.
12. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009;2(67):pe24.
13. Dias VC, Yatscoff RW. An in vitro method for predicting in vivo oral bioavailability of novel immunosuppressive drugs. Clin Biochem. 1996;29(1):43-49.
14. Maramattom BV, Wijdicks EF. Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Neurology. 2004;63(10): 1958-1959.
15. Lee SW, Chang DH, Shim MS, Kim BO, Kim SO, Seo MH. Ionically fixed polymeric nanoparticles as a novel drug carrier. Pharm Res. 2007;24(8):1508-1516.
16. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315-2319.
17. Jeong SY, Park SJ, Yoon SM, et al. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization. J Control Release. 2009;139(3):239-245.
18. Jeong SY, Yi SL, Lim SK, et al. Enhancement of radiotherapeutic effectiveness by temperature-sensitive liposomal 1-methylxanthine. Int J Pharm. 2009;372(1-2):132-139.
19. Gref R, Luck M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-313.
20. Avgoustakis K, Beletsi A, Panagi Z, et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm. 2003;259(1-2):115-127.
21. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72(1-3):191-202.
22. Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006;5(5):1183-1189.
23. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66(20):10040-10047.
24. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene. 2005;24(35): 5414-5422.
25. Aoki H, Kondo Y, Aldape K, et al. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy. 2008;4(4):467-475.
26. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
27. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2): 128-135.
28. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12(8):1007-1018.
29. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
30. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729-734.
31. Morris RE. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. Transplant Proc. 1991;23(6): 2722-2724.
32. Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001;213(1-2):25-29.
33. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. Drugs R D. 2004;5(6):363-367.
34. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22(12): 2336-2347.
35. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21(5):797-802.